Meeting
2017 ASCO Annual Meeting
A phase Ib/II, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer.
Authors
Giuseppe Del Priore
Morehouse School of Medicine, Atlanta, GA
Giuseppe Del Priore , Steve Hoffman , Daniel W. Nixon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS2615)
DOI
10.1200/JCO.2017.35.15_suppl.TPS2615
Abstract #
TPS2615
Poster Bd #
97b
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Phase 1/2a, open-label, dose-escalation and safety study of APC-100 in men with advanced prostate cancer.
First Author: Christos Kyriakopoulos
Poster
2023 ASCO Annual Meeting
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.
First Author: Kathleen N. Moore
First Author: R. Wendel Naumann
Poster
2020 ASCO Virtual Scientific Program
First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer.
First Author: Muralidhar Beeram